Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Last updated: April 11, 2013
Sponsor: GlaxoSmithKline
Overall Status: Completed

Phase

3

Condition

Bronchitis

Treatment

N/A

Clinical Study ID

NCT00269126
SCO100646
  • Ages 40-80
  • All Genders

Study Summary

This study compares the effect of two medicines on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 18 weeks, and subjects will visit the clinic 5 times. Subjects will be given breathing tests, and will record their breathing symptoms daily on diary cards.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Diagnosis of COPD.

Exclusion

Exclusion criteria:

  • Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder otherthan COPD.

  • Other inclusion and exclusion criteria will be evaluated at the first study visit.

Study Design

Total Participants: 150
Study Start date:
February 01, 2005
Estimated Completion Date:
August 31, 2005

Study Description

Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) "Assessment of the Effect of Addition of Fluticasone Dipropionate to Salmeterol Xinafoate 50µg after Switching under Double-blinded conditions to GW815SF 50/250µg in Chronic Obstructive Pulmonary Disease

Connect with a study center

  • GSK Investigational Site

    Kyoto, 602-8026
    Japan

    Site Not Available

  • GSK Investigational Site

    Unknown,
    Spain

    Site Not Available

  • GSK Investigational Site

    ,

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.